Northern Trust’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.81M | Buy |
1,419,024
+141,165
| +11% | +$620K | ﹤0.01% | 2435 |
|
|
2026
Q1 | $5.75M | Buy |
1,277,859
+41,170
| +3% | +$180K | ﹤0.01% | 2384 |
|
|
2025
Q4 | $5.95M | Sell |
1,236,689
-52,724
| -4% | -$237K | ﹤0.01% | 2371 |
|
|
2025
Q3 | $5.85M | Buy |
1,289,413
+5,194
| +0.4% | +$19.1K | ﹤0.01% | 2409 |
|
|
2025
Q2 | $3.97M | Buy |
1,284,219
+618
| +0% | +$2.05K | ﹤0.01% | 2595 |
|
|
2025
Q1 | $4.48M | Sell |
1,283,601
-47,082
| -4% | -$157K | ﹤0.01% | 2480 |
|
|
2024
Q4 | $4.35M | Buy |
1,330,683
+102,241
| +8% | +$376K | ﹤0.01% | 2584 |
|
|
2024
Q3 | $4.73M | Buy |
1,228,442
+177,117
| +17% | +$679K | ﹤0.01% | 2508 |
|
|
2024
Q2 | $3.25M | Sell |
1,051,325
-5,279
| -0.5% | -$15.8K | ﹤0.01% | 2640 |
|
|
2024
Q1 | $2.73M | Sell |
1,056,604
-11,617
| -1% | -$30.1K | ﹤0.01% | 2805 |
|
|
2023
Q4 | $2.67M | Buy |
1,068,221
+2,849
| +0.3% | +$5.58K | ﹤0.01% | 2835 |
|
|
2023
Q3 | $2.16M | Buy |
1,065,372
+21,911
| +2% | +$45.9K | ﹤0.01% | 2896 |
|
|
2023
Q2 | $2.4M | Buy |
1,043,461
+93,571
| +10% | +$244K | ﹤0.01% | 2912 |
|
|
2023
Q1 | $2.88M | Buy |
949,890
+31,149
| +3% | +$87.9K | ﹤0.01% | 2775 |
|
|
2022
Q4 | $2.14M | Buy |
918,741
+18,194
| +2% | +$43.5K | ﹤0.01% | 2962 |
|
|
2022
Q3 | $1.72M | Buy |
900,547
+3,575
| +0.4% | +$8.42K | ﹤0.01% | 3099 |
|
|
2022
Q2 | $2.43M | Buy |
896,972
+122,733
| +16% | +$314K | ﹤0.01% | 2950 |
|
|
2022
Q1 | $2.31M | Buy |
774,239
+39,771
| +5% | +$122K | ﹤0.01% | 3028 |
|
|
2021
Q4 | $2.86M | Buy |
734,468
+33,964
| +5% | +$132K | ﹤0.01% | 3034 |
|
|
2021
Q3 | $3M | Sell |
700,504
-18,655
| -3% | -$62.2K | ﹤0.01% | 3052 |
|
|
2021
Q2 | $2.18M | Buy |
719,159
+586,456
| +442% | +$1.82M | ﹤0.01% | 3312 |
|
|
2021
Q1 | $442K | Buy |
132,703
+18,500
| +16% | +$71.4K | ﹤0.01% | 3854 |
|
|
2020
Q4 | $405K | Sell |
114,203
-5,480
| -5% | -$19.2K | ﹤0.01% | 3780 |
|
|
2020
Q3 | $375K | Buy |
119,683
+16,896
| +16% | +$51.4K | ﹤0.01% | 3672 |
|
|
2020
Q2 | $188K | Buy |
+102,787
| New | +$168K | ﹤0.01% | 3776 |
|
|
2019
Q3 | – | Sell |
-293,078
| Closed | -$610K | – | 4250 |
|
|
2019
Q2 | $610K | Sell |
293,078
-20,682
| -7% | -$52.9K | ﹤0.01% | 3507 |
|
|
2019
Q1 | $1.12M | Buy |
313,760
+2,642
| +0.8% | +$10.1K | ﹤0.01% | 3319 |
|
|
2018
Q4 | $1.19M | Sell |
311,118
-20,590
| -6% | -$101K | ﹤0.01% | 3308 |
|
|
2018
Q3 | $3.13M | Buy |
331,708
+35,292
| +12% | +$350K | ﹤0.01% | 2962 |
|
|
2018
Q2 | $2.16M | Buy |
+296,416
| New | +$1.76M | ﹤0.01% | 3171 |
|
Other funds holding ABUS
TSC
WCM
RCMNY
Northern Trust's ABUS Position: Q2 2026 in Review
Northern Trust increased its Arbutus Biopharma (ABUS) stake by 11% in Q2 2026, buying an estimated $620K and bringing the position to 1,419,024 shares worth $6.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2435.
Northern Trust first reported a position in ABUS in Q2 2018 and has held it in 30 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.
- Northern Trust held 1,419,024 shares of Arbutus Biopharma worth $6.81M as of Q2 2026.
- Northern Trust bought 141,165 Arbutus Biopharma shares in Q2 2026, an estimated $620K.
- Arbutus Biopharma made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2435 holding.
- Northern Trust first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 30 quarters since.
- 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.